Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO<blockquote>苏格兰生物技术TC BioPharm将交易规模降低40%,并在3000万美元美国IPO前增加认股权证</blockquote>
TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies,
Cathie Wood says stocks have corrected into 'deep value territory' and won't let benchmarks 'hold our strategies hostage'<blockquote>凯西·伍德表示,股市已修正至“深度价值区域”,不会让基准“挟持我们的策略”</blockquote>
ARK Invest founder Cathie Wood offered the latest defense of the once-highflying, disruptive innovat